2017 - Member of the National Academy of Medicine (NAM)
1951 - Fellow of the American Association for the Advancement of Science (AAAS)
Member of the Association of American Physicians
John H. Sampson mainly investigates Internal medicine, Glioma, Immunology, Surgery and Oncology. As a part of the same scientific study, John H. Sampson usually deals with the Internal medicine, concentrating on Gastroenterology and frequently concerns with Regimen and Survival rate. His study in Glioma is interdisciplinary in nature, drawing from both Bone marrow, Pathology, Magnetic resonance imaging, Drug delivery to the brain and Volume of distribution.
The study of Immunology is intertwined with the study of Epidermal growth factor receptor in a number of ways. He interconnects Adverse effect and Urology in the investigation of issues within Surgery. His Oncology study integrates concerns from other disciplines, such as Cancer, Recurrent glioblastoma and Pharmacology.
John H. Sampson mainly focuses on Immunology, Immunotherapy, Internal medicine, Cancer research and Glioma. He has included themes like Cancer and Epidermal growth factor receptor in his Immunology study. His Immunotherapy study combines topics in areas such as Brain tumor, Dendritic cell, Clinical trial and Adoptive cell transfer.
His Internal medicine study combines topics from a wide range of disciplines, such as Surgery and Oncology. His Cancer research research is multidisciplinary, incorporating perspectives in T cell, Cytotoxic T cell, Immunotoxin and Pathology. His study on Glioma is mostly dedicated to connecting different topics, such as Toxicity.
Cancer research, Immunotherapy, Internal medicine, Oncology and Glioma are his primary areas of study. John H. Sampson has researched Cancer research in several fields, including T cell, Cancer, Interleukin-4 receptor and CD3. Immunotherapy is a subfield of Immune system that John H. Sampson explores.
The subject of his Immune system research is within the realm of Immunology. The Oncology study combines topics in areas such as Survival rate and Chemotherapy, Temozolomide. His work carried out in the field of Glioma brings together such families of science as Rhinovirus, Immunotoxin, Antibody and Toxicity.
John H. Sampson mostly deals with Immunotherapy, Cancer research, Internal medicine, Oncology and Immune system. His biological study spans a wide range of topics, including Tumor microenvironment, Immunosuppression and Oncolytic virus. His research integrates issues of Cancer cell, Cancer, Reprogramming, T cell and Stem cell in his study of Cancer research.
His study in Clinical trial, Randomized controlled trial and Regimen falls within the category of Internal medicine. His studies in Oncology integrate themes in fields like Survival rate and Glioblastoma, Glioma, Temozolomide. John H. Sampson combines subjects such as Combined Modality Therapy, Antibody titer, Germinal center and Bioinformatics with his study of Immune system.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
James J. Vredenburgh;Annick Desjardins;James E. Herndon;Jennifer Marcello.
Journal of Clinical Oncology (2007)
Phase II Trial of Gefitinib in Recurrent Glioblastoma
Jeremy N. Rich;David A. Reardon;Terry Peery;Jeannette M. Dowell.
Journal of Clinical Oncology (2004)
Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma
John H. Sampson;Amy B Heimberger;Gary E. Archer;Kenneth D. Aldape.
Journal of Clinical Oncology (2010)
Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma
John H. Sampson;James H. Carter;Allan H. Friedman;Hilliard F. Seigler.
Journal of Neurosurgery (1998)
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.
Peter E. Fecci;Duane A. Mitchell;John F. Whitesides;Weihua Xie.
Cancer Research (2006)
Proteomic and immunologic analyses of brain tumor exosomes
Michael W. Graner;Oscar Alzate;Angelika M. Dechkovskaia;Jack D. Keene.
The FASEB Journal (2009)
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.
Sandeep Kunwar;Susan Chang;Manfred Westphal;Michael Vogelbaum.
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.
Hideho Okada;Michael Weller;Raymond Huang;Gaetano Finocchiaro.
Lancet Oncology (2015)
Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma
Duane A. Mitchell;Weihua Xie;Robert Schmittling;Chris Learn.
Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients
Duane A. Mitchell;Kristen A. Batich;Michael D. Gunn;Min-Nung Huang.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: